Neuropathic POTS is the most common subtype of postural orthostatic tachycardia syndrome, driven by damage to the small nerve fibers that help blood vessels tighten when you stand up. Because those nerves don’t fire properly, blood pools in the legs and abdomen, and the heart races to compensate. The distinction matters because it shapes which treatments work best and what kind of testing can confirm the diagnosis. Understanding the neuropathic subtype specifically, rather than POTS as a catch-all, gives patients and clinicians a sharper framework for managing symptoms.
What Makes Neuropathic POTS Different From Other Subtypes
POTS is not a single disease but a collection of subtypes that share the hallmark heart rate surge upon standing. The neuropathic form is characterized by decreased ability of small blood vessels to constrict in response to signals from the sympathetic nervous system. A study comparing neuropathic and hyperadrenergic POTS directly confirmed this distinction: neuropathic POTS involves decreased adrenergic vasoconstriction, while hyperadrenergic POTS involves increased adrenergic vasoconstriction.1PubMed Central. A double-blind placebo-controlled cross-over study of the vascular effects of midodrine in neuropathic compared with hyperadrenergic postural tachycardia syndrome The practical consequence is that blood redistributes passively into the veins of the legs and pelvis when the arteries fail to narrow properly.2PubMed. Pooling in chronic orthostatic intolerance: arterial vasoconstrictive but not venous compliance defects
In contrast, hyperadrenergic POTS is typically marked by surges in norepinephrine that cause blood pressure spikes, tremor, and anxiety-like symptoms. A third category sometimes referenced is hypovolemic POTS, characterized by abnormally low blood volume rather than nerve damage.3PubMed Central. Cutaneous manifestations of orthostatic intolerance syndromes These categories overlap in many patients, and someone can have features of more than one subtype. Still, when nerve fiber damage is confirmed through testing, the neuropathic label opens doors to more targeted treatment strategies.
The Role of Small Fiber Neuropathy
The nerve damage behind neuropathic POTS involves the thinnest nerve fibers in the body, the ones responsible for sweating, temperature sensation, pain, and the moment-to-moment regulation of blood vessel tone. When these fibers are damaged or die back from the skin and blood vessels, two things go wrong simultaneously: the blood vessels in the lower body lose their ability to constrict on command, and the sensory nerves that detect changes in blood flow can no longer relay accurate signals to the brain.
Research has shown that this damage extends beyond the skin. A subset of neuropathic POTS patients have reduced nerve fiber density in skin biopsies alongside reduced sympathetic nerve supply to the heart itself.4PubMed. Small-fiber neuropathy with cardiac denervation in postural tachycardia syndrome That finding is worth pausing on, because it means the autonomic nerve damage is not confined to the extremities. It can affect the heart’s own regulation, which may explain why some patients experience palpitations and erratic heart rate changes that go beyond simple standing-related tachycardia.
The patchy nature of this denervation is a defining feature. Unlike many neuropathies that progress in a predictable stocking-glove pattern from the toes upward, the nerve fiber loss in neuropathic POTS can be patchy and uneven, affecting different body regions to different degrees. This patchiness helps explain the wide variability in symptoms from one patient to the next.
Symptoms to Watch For
The core symptom of all POTS subtypes is an excessive heart rate increase upon standing, typically 30 beats per minute or more within the first ten minutes. But neuropathic POTS tends to come with a broader package of complaints that reflect the underlying nerve damage.
Common symptoms include:
- Blood pooling: Visible discoloration of the feet and lower legs upon standing, sometimes described as a reddish-purple or mottled appearance. This occurs because blood accumulates in the veins when arteries fail to constrict.
- Lightheadedness and near-fainting: Reduced blood flow to the brain upon standing, sometimes progressing to actual fainting in severe cases.
- Exercise intolerance: Difficulty sustaining physical activity, especially upright exercise, because of worsened pooling and heart rate surges.
- Sweating abnormalities: Patchy areas of reduced or absent sweating, reflecting damage to the sudomotor nerves. Some patients also report excessive sweating in unaffected areas as the body tries to compensate.
- Burning or tingling in the extremities: Because the same small fibers carry pain and temperature signals, their damage often produces neuropathic pain symptoms in the hands and feet.
- Gastrointestinal problems: Nausea, bloating, early fullness, and gastroparesis-like symptoms can occur when small fibers supplying the gut are affected.
Many of these symptoms are shared across POTS subtypes, but the combination of visible blood pooling, abnormal sweating patterns, and neuropathic pain in the extremities leans toward the neuropathic form. A study of quality of life in POTS patients found that the level of functional impairment was comparable to that of patients with chronic obstructive pulmonary disease or congestive heart failure, conditions that typically affect a much older population.5Mayo Clinic Proceedings. Quality of Life in Patients With Postural Tachycardia Syndrome That comparison is striking given that POTS overwhelmingly affects younger people, often in their teens through thirties.
How Neuropathic POTS Is Diagnosed
Diagnosing POTS in general starts with a tilt table test or an active standing test that documents the characteristic heart rate increase. Identifying the neuropathic subtype specifically requires additional testing aimed at detecting small fiber nerve damage.
The two most informative tests are skin biopsy and sweat testing. In a study of POTS patients who underwent both, about a quarter of those biopsied showed reduced nerve fiber density in the skin, and roughly a third of those who had sweat testing showed reduced sweat output.6PubMed Central. Skin Biopsy and Quantitative Sudomotor Axon Reflex Testing in Patients With Postural Orthostatic Tachycardia Syndrome Those numbers tell you something important: not every POTS patient has detectable nerve fiber loss, and the two tests don’t always agree. A normal skin biopsy doesn’t rule out neuropathic POTS if sweat testing is abnormal, and vice versa. Running both tests together catches more cases than either alone.
Skin biopsy involves taking a small punch biopsy, usually from the lower leg and sometimes from the thigh, and counting the number of nerve fibers that cross into the outer layer of skin. The procedure is quick and minimally invasive. Sweat testing, called quantitative sudomotor axon reflex testing (QSART), measures how much sweat the skin produces in response to a chemical stimulus applied at several body sites. Reduced output at one or more sites suggests sudomotor nerve damage.
Beyond these two tests, thermoregulatory sweat testing, which maps the body’s entire sweat pattern, can reveal the patchy distribution of nerve loss. Autonomic reflex screening, which includes assessment of heart rate variability and blood pressure responses to various challenges, rounds out the picture. No single test is a perfect detector, so clinicians typically use a combination.
The Autoimmune Connection
One of the most active areas of POTS research involves the question of whether the nerve damage is caused by the body’s own immune system attacking the autonomic nerves. The evidence is building but not yet conclusive. Studies have found that many POTS patients carry autoantibodies targeting receptors on the autonomic nervous system, including adrenergic and muscarinic acetylcholine receptors.7PubMed Central. Postural Orthostatic Tachycardia Syndrome Is Associated With Elevated G-Protein Coupled Receptor Autoantibodies A systematic review confirmed the presence of adrenergic and cholinergic receptor antibodies across multiple studies of POTS and orthostatic intolerance.8PubMed. The role of autoantibodies in the syndromes of orthostatic intolerance: a systematic review
These autoantibodies could theoretically interfere with nerve signaling to blood vessels, either by blocking or overstimulating the receptors, ultimately contributing to the impaired vasoconstriction that defines neuropathic POTS. This autoimmune hypothesis also helps explain why POTS so often appears after an infection. The immune system, revved up to fight a virus, may inadvertently generate antibodies that cross-react with the body’s own nerve receptors.
Testing for these antibodies is available through specialized laboratories, but interpretation remains tricky. Elevated antibody levels don’t always correlate neatly with symptom severity, and healthy people can sometimes have low levels of the same antibodies. The clinical significance of a positive result depends heavily on context, particularly whether the patient has other markers of autoimmunity or a clear post-infectious onset.
Post-Viral Triggers and Long COVID
POTS has long been associated with viral infections, and the COVID-19 pandemic brought this connection into sharper focus. Many patients developed POTS symptoms weeks to months after a SARS-CoV-2 infection, consistent with the broader phenomenon of long COVID. The suspected mechanism mirrors the autoimmune pathway: viral illness triggers an immune response that produces antibodies cross-reacting with autonomic nerve receptors, including adrenergic, acetylcholine, and angiotensin II receptors.9PubMed Central. COVID-19 Induced Postural Orthostatic Tachycardia Syndrome (POTS): A Review
COVID-19 is not unique in this regard. Epstein-Barr virus, influenza, and other common infections have all been implicated as POTS triggers in case series dating back well before the pandemic. What the pandemic did was dramatically increase the number of new POTS cases appearing in autonomic clinics, expanding both public awareness and research funding. For patients whose neuropathic POTS began after a clear viral illness, the post-infectious framing can guide treatment decisions, particularly the consideration of immunomodulatory therapies.
Pharmacological Treatment
There is no single drug approved specifically for POTS, so treatment is built from medications used for related conditions and tailored to the individual subtype. For neuropathic POTS, the pharmacological strategy generally targets two goals: improving blood vessel constriction and controlling the heart rate surge.
Midodrine, an alpha-1 adrenergic agonist, works by directly tightening blood vessels, partly compensating for the nerve damage that prevents normal vasoconstriction. The same study that distinguished neuropathic from hyperadrenergic POTS examined midodrine’s effects in both groups and confirmed its vascular action in neuropathic patients.1PubMed Central. A double-blind placebo-controlled cross-over study of the vascular effects of midodrine in neuropathic compared with hyperadrenergic postural tachycardia syndrome Fludrocortisone, a mineralocorticoid that promotes salt and water retention to expand blood volume, is another common first-line medication. Both are used widely across POTS subtypes, but the rationale in neuropathic POTS specifically targets the pooling mechanism.
For heart rate control, ivabradine has emerged as a promising option. It slows the heart rate without lowering blood pressure, which is a critical advantage in POTS patients who often already run low. In a study of POTS patients given ivabradine, the heart rate during a head-up tilt test dropped from about 118 beats per minute to about 101 beats per minute, with no effect on blood pressure.10PubMed Central. The Effect of Ivabradine on the Heart Rate and Sympathovagal Balance in Postural Tachycardia Syndrome Patients A separate study found that patients with the neuropathic subtype maintained their treatment response to ivabradine for a median of about 27 months, compared to roughly 11 months for non-neuropathic patients, suggesting the drug may be particularly well suited to this group.11PubMed Central. Maximizing treatment response in patients with neuropathic-subtype postural orthostatic tachycardia syndrome
Beta-blockers, the traditional go-to for rate control, are used cautiously in neuropathic POTS because they can lower blood pressure and worsen the pooling-related symptoms. Low doses of propranolol are sometimes helpful, but higher doses often backfire.
Immunotherapy for Autoimmune-Driven Cases
When autoimmune markers are present and the neuropathic POTS appears to be immune-mediated, immunomodulatory treatments come into consideration. Intravenous immunoglobulin (IVIG) has generated the most interest, and individual case reports have described patients stabilizing on immunoglobulin therapy and transitioning to subcutaneous maintenance dosing with fewer side effects.12Journal of Translational Autoimmunity. Maintenance therapy with subcutaneous immunoglobulin in a patient with immune‐mediated neuropathic postural tachycardia syndrome
The picture at the trial level is less encouraging so far. A randomized controlled trial comparing IVIG to albumin infusion in POTS patients found no statistically significant difference in overall symptom improvement between the two groups.13PubMed. Randomized controlled trial of intravenous immunoglobulin for autoimmune postural orthostatic tachycardia syndrome (iSTAND) The IVIG group had a slightly higher response rate, but the trial was small and the difference was not meaningful statistically. This doesn’t necessarily mean IVIG is ineffective. It may mean that only a specific subset of autoimmune POTS patients responds, and that current trials haven’t been powered or selected well enough to identify that subset. Immunotherapy remains an option typically reserved for severe, refractory cases with clear autoimmune evidence, and its cost and side-effect burden are substantial.
Exercise Training and Non-Drug Strategies
Exercise is one of the most consistently effective interventions for POTS, including the neuropathic form, but it has to be approached carefully. The standard recommendation is to start with recumbent or semi-recumbent exercise such as rowing, swimming, or recumbent cycling, because these positions avoid the upright posture that triggers symptoms. As fitness improves, patients can gradually transition to more upright activities.14PubMed Central. Exercise and non-pharmacological treatment of POTS
The results of structured programs can be dramatic. In a registry-based study, 103 POTS patients completed a three-month program of progressively increasing endurance and strength training combined with increased salt and water intake. After the program, 71% no longer met the diagnostic criteria for POTS. The average heart rate increase on standing dropped from 46 beats per minute to 23 beats per minute, and quality of life improved substantially.15PubMed. The international POTS registry: Evaluating the efficacy of an exercise training intervention in a community setting Those numbers are remarkable, but they also include a self-selection bias: the patients who completed the program were presumably those well enough to tolerate it, and dropout rates in exercise trials for POTS tend to be high.
Other non-drug strategies work alongside exercise. Increasing daily fluid intake to two to three liters and adding extra dietary salt helps expand blood volume, which counteracts the pooling problem. Compression garments, particularly waist-high stockings or abdominal binders, physically push blood back toward the heart. Sleeping with the head of the bed slightly elevated can help retain fluid overnight by reducing nighttime urination. These interventions are considered foundational and are typically recommended before or alongside medications.
Overlapping Conditions That Complicate the Picture
Neuropathic POTS rarely exists in isolation. Two conditions that show up disproportionately alongside POTS are Ehlers-Danlos syndrome (EDS), a connective tissue disorder, and mast cell activation syndrome (MCAS), a condition involving abnormal immune cell activity. A study examining the overlap found that patients who had both POTS and EDS were far more likely to also have MCAS, with an odds ratio of about 32 compared to patients with EDS alone.16PubMed. The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome
This triad, sometimes informally called “the trifecta” in patient communities, creates a layered clinical picture. The hypermobile joints in EDS may allow veins to stretch more than normal, worsening blood pooling. MCAS can contribute flushing, gastrointestinal symptoms, and inflammatory episodes that overlap with and amplify POTS symptoms. For patients with neuropathic POTS who aren’t improving with standard treatment, screening for these co-occurring conditions can uncover additional targets for therapy. Antihistamines and mast cell stabilizers, for instance, can help if MCAS is part of the picture.
Prognosis and What Adolescents Can Expect
One of the most common questions patients ask is whether they will get better. The answer depends on age of onset, triggers, and subtype, but the data is more encouraging than many patients expect. A follow-up study of adolescents with POTS found that about 19% reported complete resolution of symptoms and an additional 51% reported persistent but improved symptoms, assessed on average five years after initial treatment. Overall, about 86% of adolescents fell into the resolved, improved, or only intermittently symptomatic category.17ScienceDirect (The Journal of Pediatrics). Outcomes of Adolescent-Onset Postural Orthostatic Tachycardia Syndrome
Those adolescent outcomes are broadly better than what adults typically experience, though rigorous long-term data in adult neuropathic POTS specifically is still sparse. Patients whose POTS began after a clear viral trigger may have a better chance of improvement than those with an insidious, unexplained onset. Similarly, patients who can tolerate and maintain an exercise program tend to do better over time than those who remain sedentary, though the direction of causality there is hard to untangle since sicker patients are less likely to exercise in the first place.
For the neuropathic subtype specifically, the trajectory likely depends on whether the underlying nerve damage is stable or progressive. In cases driven by a one-time autoimmune insult, such as post-viral nerve injury, there may be a window for partial nerve regeneration, since small fibers do have some capacity to regrow. In cases where an ongoing autoimmune process continues to damage nerves, the outlook without immunomodulation may be less favorable, though this remains an area where firm evidence is still catching up with clinical intuition.
Why Subtyping Matters for Treatment Selection
Treating POTS as a monolith, as though every patient has the same underlying problem, is one of the reasons patients often cycle through multiple failed medications before finding something that helps. The neuropathic subtype responds to vasoconstrictors and volume expanders in a way that makes physiological sense: if blood vessels can’t tighten on their own, give them a drug that tightens them, and if blood volume is being pulled out of the effective circulation by pooling, push more fluid in. The hyperadrenergic subtype, by contrast, may worsen on vasoconstrictors that raise already-elevated norepinephrine-driven blood pressure.
The ivabradine data illustrates this nicely. Neuropathic patients maintained their response for more than twice as long as non-neuropathic patients.11PubMed Central. Maximizing treatment response in patients with neuropathic-subtype postural orthostatic tachycardia syndrome That kind of finding should change clinical behavior: if you know a patient has confirmed small fiber neuropathy on biopsy or sweat testing, starting ivabradine rather than a beta-blocker becomes a more evidence-guided choice. The testing investment up front, including skin biopsy, sweat testing, and autoantibody panels, pays for itself in fewer medication trials and faster stabilization.
Getting subtyped is not always easy. Many general cardiologists and even some neurologists are unfamiliar with the workup, and autonomic specialty clinics often have long wait times. Patients who suspect neuropathic POTS based on their symptom profile, particularly those with burning extremity pain, visible pooling, and sweating abnormalities, can advocate for a skin biopsy and QSART even before seeing an autonomic specialist. These tests are available at most academic medical centers and some community neurology practices.